Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open‐Label, Crossover, Randomized, Controlled, Phase I Clinical Trial
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70011 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Mulin Yi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, P. R. C…. Hauptthemen laut MEDLINE: Food-Drug Interactions, Androstenes. Die Arbeit nennt 34 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Hunan Provincial grants.
Abstract (Originalsprache)
This first‐in‐human phase I trial evaluated RL001, a self‐emulsifying soft‐capsule abiraterone developed to overcome the low bioavailability and food sensitivity associated with the 1000‐mg Zytiga tablet that is used with prednisone according to NCCN guidelines. Plasma concentrations were quantified by LC‐MS/MS and modeled in Phoenix WinNonlin 8.1 and SAS; GeoMean confidence intervals compared pharmacokinetics. Against 1000‐mg abiraterone acetate tablet, the 200 mg RL001 achieved abiraterone C max GMR >125% and AUC 0‐t , AUC 0‐∞ 80–125%, indicating higher bioavailability and enabling a lower therapeutic dose. The GMR of prednisone and its metabolite remained within 80%–125%, confirming no interaction. Fed/fasted exposure ratios stayed around 80% for AUC and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, P. R. China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, P. R. China.
- MOE Key Lab of Rare Pediatric Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan, P. R. China.
- NHC Key Laboratory of Birth Defect for Research and Prevention, Changsha, Hunan, China.
Förderung
- the National Natural Science Foundation of China
- Hunan Provincial grants
Zitieren
APA
Yi, M., Tu, S., Cheng, Z., & Xia, K. (2026). Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open‐Label, Crossover, Randomized, Controlled, Phase I Clinical Trial. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70011
Vancouver
Yi M, Tu S, Cheng Z, Xia K. Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open‐Label, Crossover, Randomized, Controlled, Phase I Clinical Trial. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70011
BibTeX
@article{Yi2026,
author = {Yi, Mulin and Tu, Shiqi and Cheng, Zeneng and Xia, Kun},
title = {Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open‐Label, Crossover, Randomized, Controlled, Phase I Clinical Trial},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70011}
}
EUVIMED